| GC33745-10mg |
|
357336-17-5 |
Anticonvulsant agent 1 (4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide)
|
0 |
C10H14F2N2O2 |
|
|
|
| GC33745-5mg |
|
357336-17-5 |
Anticonvulsant agent 1 (4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide)
|
0 |
C10H14F2N2O2 |
|
|
|
| GC33745-1mg |
|
357336-17-5 |
Anticonvulsant agent 1 (4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide)
|
0 |
C10H14F2N2O2 |
|
|
|
| GC33744-20mg |
|
30279-49-3 |
Suclofenide (Neosulfalepsine)
|
0 |
C16H13ClN2O4S |
|
|
|
| GC33744-10mg |
|
30279-49-3 |
Suclofenide (Neosulfalepsine)
|
0 |
C16H13ClN2O4S |
|
|
|
| GC33744-5mg |
|
30279-49-3 |
Suclofenide (Neosulfalepsine)
|
0 |
C16H13ClN2O4S |
|
|
|
| GC33744-1mg |
|
30279-49-3 |
Suclofenide (Neosulfalepsine)
|
0 |
C16H13ClN2O4S |
|
|
|
| GC33743-100mg |
|
1254698-46-8 |
|
0 |
C25H27N3O4 |
|
|
|
| GC33743-10mg |
|
1254698-46-8 |
|
0 |
C25H27N3O4 |
|
|
|
| GC33743-50mg |
|
1254698-46-8 |
|
0 |
C25H27N3O4 |
|
|
|
| GC33743-5mg |
|
1254698-46-8 |
|
0 |
C25H27N3O4 |
|
|
|
| GC33742-5g |
|
614-75-5 |
2-Hydroxyphenylacetic acid
|
0 |
C8H8O3 |
|
|
|
| GC33740-5mg |
|
117928-93-5 |
|
0 |
C18H30N4O7 |
|
|
|
| GC33740-1mg |
|
117928-93-5 |
|
0 |
C18H30N4O7 |
|
|
|
| GC33739-500mg |
|
554-52-9 |
3-Methoxytyramine (3-O-methyl Dopamine)
|
0 |
C9H13NO2 |
|
|
|
| GC33739-250mg |
|
554-52-9 |
3-Methoxytyramine (3-O-methyl Dopamine)
|
0 |
C9H13NO2 |
|
|
|
| GC33739-100mg |
|
554-52-9 |
3-Methoxytyramine (3-O-methyl Dopamine)
|
0 |
C9H13NO2 |
|
|
|
| GC33738-1g |
|
1477-68-5 |
3-Methoxytyramine hydrochloride (3-O-methyl Dopamine hydrochloride)
|
0 |
C9H14ClNO2 |
|
|
|
| GC33738-500mg |
|
1477-68-5 |
3-Methoxytyramine hydrochloride (3-O-methyl Dopamine hydrochloride)
|
0 |
C9H14ClNO2 |
|
|
|
| GC33738-250mg |
|
1477-68-5 |
3-Methoxytyramine hydrochloride (3-O-methyl Dopamine hydrochloride)
|
0 |
C9H14ClNO2 |
|
|
|
